By Fineline Cube Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company’s proprietary artificial intelligence platform, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable malignant pleural mesothelioma who have progressed following anti-PD-1 antibody therapy and platinum-based chemotherapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Insilico Medicine (HKG: 3696) |
| Drug Candidate | ISM6331 |
| Regulatory Agency | U.S. Food and Drug Administration (FDA) |
| Designation | Fast Track Designation (FTD) |
| Indication | Unresectable malignant pleural mesothelioma (post anti-PD-1 ± anti-CTLA-4 + platinum chemo) |
| Previous Designation | Orphan Drug Designation (ODD) granted in 2024 |
| Announcement Date | 29 Jul 2026 |
Drug Profile & Mechanism
AI-Driven Discovery
- Platform Origin: Discovered using Insilico’s proprietary AI drug discovery platform
- Structure Design: Novel non-covalent structure guided by Chemistry42’s structure-based drug design strategy
- Target Class: Pan-TEAD inhibitor – potential best-in-class candidate
- Development Stage: Currently in global multicenter Phase I trial (first patient dosed January 2025)
Therapeutic Mechanism
- Primary Target: Tumors with Hippo pathway abnormalities
- Combination Potential: Demonstrates synergistic anti-tumor effects in combination therapy
- Resistance Management: Shows ability to overcome drug resistance mechanisms
- Broad Applicability: Targets fundamental oncogenic pathway across multiple tumor types
Preclinical & Clinical Data
Preclinical Profile
- Efficacy: Demonstrated broad anti-tumor efficacy across multiple models
- Potency: High activity at low doses – favorable therapeutic index
- Safety: Favorable safety profile with strong ADMET characteristics
- Selectivity: Specific targeting of TEAD transcription factors with minimal off-target effects
Clinical Development Status
- Phase I Trial: Global multicenter study initiated January 2025
- Patient Population: Heavily pre-treated mesothelioma patients with limited options
- Trial Design: Dose escalation followed by expansion cohorts in specific indications
- Regulatory Pathway: Accelerated development supported by FTD and ODD designations
Market Context & Strategic Value
Mesothelioma Treatment Landscape
- Unmet Need: Malignant pleural mesothelioma remains largely incurable with median survival of 12-18 months
- Treatment Gap: Limited effective options after progression on standard immunotherapy and chemotherapy
- Patient Population: Approximately 3,000 new cases annually in the US, with similar burden globally
- Commercial Incentives: Orphan drug exclusivity combined with fast track development creates attractive regulatory pathway
AI Drug Discovery Validation
- Platform Credibility: ISM6331 represents validation of Insilico’s end-to-end AI drug discovery capabilities
- Investor Confidence: Demonstrates AI can identify novel targets and generate clinical candidates with differentiated profiles
- Competitive Advantage: Positions Insilico as leader in AI-discovered oncology therapeutics
- Pipeline Implications: Success validates platform for other TEAD-dependent cancers and transcription factor targets
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory designations, and commercial expectations. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive developments.-Fineline Info & Tech